SCHEMBL23948546

SCHEMBL23948546

N#Cc1cc(Cl)c(N)cc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KHK P50053 1/20 0.47
TRPV4 Q9HBA0 3/20 0.45
GAA P10253 1/20 0.44
CYP11B2 P19099 4/20 0.37
CYP11B1 P15538 2/20 0.37
ALDH1A1 P00352 1/20 0.36
EGLN2 Q96KS0 2/20 0.33
CSNK1A1 P48729 1/20 0.33
CLK4 Q9HAZ1 1/20 0.33
CYP2D6 P10635 1/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
NOS2 P35228 1/20 0.33
ADRB2 P07550 1/20 0.33
ADRB1 P08588 1/20 0.33
MAPK1 P28482 1/20 0.33
NPC1 O15118 1/20 0.32
TSHR P16473 2/20 0.32
CYP3A4 P08684 1/20 0.32
TP53 P04637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL405495 0.83 KHK (0.47) KHKTRPV4GAACYP11B2CYP11B1
SCHEMBL8462168 0.82 TRPV4 (0.52) KHKTRPV4CYP11B2CYP11B1ALDH1A1
SCHEMBL6402873 0.82 GAA (0.52) KHKTRPV4GAAALDH1A1CSNK1A1
SCHEMBL2314240 0.82 TRPV4 (0.52) KHKTRPV4GAACYP11B2CYP11B1
SCHEMBL7073779 0.80 GAA (0.57) KHKTRPV4GAACYP11B2ALDH1A1
SCHEMBL30498666 0.80 GAA (0.57) KHKTRPV4GAACYP11B2ALDH1A1
SCHEMBL286611 0.80 TRPV4 (0.50) KHKTRPV4CYP11B2CYP11B1ALDH1A1
SCHEMBL29513067 0.80 TRPV4 (0.50) KHKTRPV4CYP11B2CYP11B1ALDH1A1
SCHEMBL10947192 0.80 TRPV4 (0.56) KHKTRPV4CYP11B2CYP11B1ALDH1A1
SCHEMBL332547 0.80 TRPV4 (0.56) KHKTRPV4GAACYP11B2CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114315834-B Imidazolone derivatives and their use in medicine 成都百裕制药股份有限公司 2024-01-05 CN disclosed
US-20230165867-A1 IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) 2023-06-01 US disclosed
EP-4137491-A1 IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) 2023-02-22 EP disclosed
EP-4137491-A1 IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) 2023-02-22 EP disclosed
CN-114315834-A Imidazolidinone derivatives and their use in medicaments 成都百裕制药股份有限公司 2022-04-12 CN disclosed
WO-2021209055-A1 IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE 成都百裕制药股份有限公司 2021-10-21 WO disclosed
WO-2021209055-A1 IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE 成都百裕制药股份有限公司 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230165867-A1 IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF SYMPK, PAICS, CYP2C9 KHK 154/4885TRPV4 2970/4885GAA 2222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.